他莫昔芬治疗下墨西哥梅斯蒂索患者的内昔芬水平及代谢表型相关因素
Endoxifen levels and metabolic phenotype-associated factors in Mexican Mestizo patients under tamoxifen treatment.
作者信息
Jorge-Aarón Rangel-Méndez, Rodrigo Rubi-Castellanos, Esther Moo-Puc Rosa
机构信息
Unidad de Investigación Biomédica, Unidad Médica de Alta Especialidad, Hospital de Especialidades del Centro Médico Nacional "Ignacio García Téllez", Instituto Mexicano del Seguro Social, Calle 41 No. 439, Col. Industrial, Mérida, Yucatán, 97150, México.
Centro de Investigaciones Regionales "Dr. Hideyo Noguchi" Calle 96 S/N, Avenida Jacinto Canek y calle 47, Paseo de las Fuentes, Merida, Yucatan, 97225, Mexico.
出版信息
Pharmacogenomics. 2020 Aug;21(13):929-943. doi: 10.2217/pgs-2020-0061. Epub 2020 Aug 18.
To evaluate plasma endoxifen levels and metabolic phenotype-associated factors in Mexican Mestizo patients under tamoxifen treatment. A total of 138 breast cancer patients under tamoxifen treatment were cross-sectionally evaluated and side effects (SE) were recorded. genetic phenotypes (GP) and metabolic phenotypes (MP) were assessed (metabolic poor [mPM], intermediate [mIM], normal [mNM], and ultrarapid [mUM] metabolizer). Associations were tested in uni-multivariate models for endoxifen >5.9 ng/ml and for mNM + mUM MP. The main SE was hot flashes (62%). Distribution of the MP was 4.3% mPM; 14.5% mIM; 75.4% mNM; and 5.8% mUM. Endoxifen >5.9 ng/ml was partially associated with SE (p = 0.06); the mNM + mUM MP was associated with treatment time (p = 0.03). The endoxifen-associated factors in Mexican Mestizo patients remain inconclusive, although treatment time was associated with MP.
评估接受他莫昔芬治疗的墨西哥梅斯蒂索患者的血浆内昔芬水平及代谢表型相关因素。对138例接受他莫昔芬治疗的乳腺癌患者进行横断面评估，并记录副作用（SE）。评估遗传表型（GP）和代谢表型（MP）（代谢不良[mPM]、中间型[mIM]、正常[mNM]和超快速[mUM]代谢者）。在单变量和多变量模型中测试内昔芬>5.9 ng/ml以及mNM + mUM MP的相关性。主要副作用为潮热（62%）。MP的分布为：4.3%为mPM；14.5%为mIM；75.4%为mNM；5.8%为mUM。内昔芬>5.9 ng/ml与副作用部分相关（p = 0.06）；mNM + mUM MP与治疗时间相关（p = 0.03）。尽管治疗时间与MP相关，但墨西哥梅斯蒂索患者中内昔芬相关因素仍不明确。
Zotero 插件